NLS Pharmaceutics AG
NASDAQ:NLSP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AddLife AB
STO:ALIF B
|
SE |
NLS Pharmaceutics AG
Other Current Assets
NLS Pharmaceutics AG
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Other Current Assets
$110.7k
|
CAGR 3-Years
-24%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Other Current Assets
$3.5B
|
CAGR 3-Years
46%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
|
Roche Holding AG
SIX:ROG
|
Other Current Assets
CHf3.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
O
|
Oculis Holding AG
NASDAQ:OCS
|
Other Current Assets
CHf135.8m
|
CAGR 3-Years
265%
|
CAGR 5-Years
355%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Other Current Assets
$315m
|
CAGR 3-Years
33%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
NLS Pharmaceutics AG
Glance View
NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder. The company is headquartered in Stans, Nidwalden and currently employs 6 full-time employees. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.
See Also
What is NLS Pharmaceutics AG's Other Current Assets?
Other Current Assets
110.7k
USD
Based on the financial report for Dec 31, 2024, NLS Pharmaceutics AG's Other Current Assets amounts to 110.7k USD.
What is NLS Pharmaceutics AG's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
0%
Over the last year, the Other Current Assets growth was -88%. The average annual Other Current Assets growth rates for NLS Pharmaceutics AG have been -24% over the past three years .
